Sudo Biosciences Raises $37M in Series A Financing
- Sudo Biosciences, a Menlo Park, CA-based biopharmaceutical company, raised $37M in Series A funding
- The round was led by Frazier Life Sciences with participation from Velosity Capital
- The company intends to use the funds to advance its lead drug candidates into the clinic
- SudoBiosciences is a biopharmaceutical company focused on designing and developing medicines to improve patients’ lives. The company’s programs target the tyrosine kinase 2 (TYK2) pseudokinase domain
- TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions
- SudoBiosciences also has operations in Indianapolis, IN and London, UK
